+++
title = 'Gufic BioSciences Ltd - Feb 2025 Earnings Call Transcript Analysis'
date = 2025-02-21 13:55:34
readTime = true
tags = ["Gufic Biosciences Ltd.", "GUFICBIO", "Branded Medicines", "Healthcare","Small Cap", "Earnings Call"]
showTags = true
toc = true
+++



## Earnings Call Transcript Analysis Report
## Financial Performance

### Key Financial Metrics (Q3 FY25 vs Q3 FY24)

*   **Total Revenue from Operations:** INR 207.8 crores (up from INR 201.8 crores).
    *   Quote (CFO): "The total revenue for the operation for the financial year '24- '25 in Q3 is INR 207.8 crores compared to Q3 of financial year '23- '24 of INR 201.8 crores."
*   **EBITDA:** INR 35.8 crores (down from INR 36.9 crores).
*   **EBITDA Margin:** 17.23% (down from 18.29%).
*   **Profit Before Tax (PBT):** INR 26.3 crores (down from INR 29.6 crores).
*   **PBT Margin:** 12.66% (down from 14.67%).
*   **Profit After Tax (PAT):** INR 19.4 crores (down from INR 22.3 crores).
*   **PAT Margin:** 9.34% (down from 11.05%).

### Key Financial Metrics (9M FY25 vs 9M FY24)

*   **Total Revenue from Operations:** INR 614.8 crores (slightly down from INR 616.7 crores).
*   **EBITDA:** INR 111.6 crores (slightly down from INR 112.9 crores).
*   **EBITDA Margin:** 18.15% (slightly down from 18.31%).
*   **Profit Before Tax (PBT):** INR 83.6 crores (down from INR 88.6 crores).
*   **PBT Margin:** 13.60% (down from 14.37%).
*   **Profit After Tax (PAT):** INR 61.9 crores (down from INR 66.1 crores).
*   **PAT Margin:** 10.07% (down from 10.72%).

### Revised Guidance or Forecasts

*   Indore facility expected to generate INR 6 crores in Q3 FY25, with Q4 FY25 revenue projected at INR 20 crores (CFO) or 2-3x of Q3 (CEO).
*   Indore facility FY26 revenue forecast: "minimum INR150 crores additional revenue" (CFO).
*   Margin pressure expected in the near term due to Indore start-up costs, with improvement anticipated post-FY26.
    *   Quote (CFO): "after '26, when the capacity utilization of Indore will be picked up, I think that the EBITDA margin and PAT margin is going to improve after '26 onwards."

### Areas of Growth or Decline

*   Revenue showed slight YoY growth for Q3 but was flat for 9M.
*   EBITDA, PBT, and PAT declined both YoY for Q3 and for the 9M period, with corresponding margin compression.



{{< rawhtml >}}

<div class="button-container">    
    <a href="http://gufic.com/Notice/Written%20Transcript%2017022025.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    
{{< /rawhtml >}}
